Michael C Donohue

List of Publications by Citations

79 papers	6,817 citations	34 h-index	82 g-index
94 ext. papers	8,285 ext. citations	5.9 avg, IF	5.55 L-index

#	Paper	IF	Citations
79	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurology, The*, **2013**, 12, 207-16	24.1	2557
78	The A4 study: stopping AD before symptoms begin?. *Science Translational Medicine*, **2014**, 6, 228fs13	17.5	455
77	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. *JAMA Neurology*, **2014**, 71, 961-70	17.2	372
76	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. *Alzheimer's and Dementia*, **2010**, 6, 239-46	1.2	308
75	The association between lower extremity continuous peripheral nerve blocks and patient falls after knee and hip arthroplasty. *Anesthesia and Analgesia*, **2010**, 111, 1552-4	3.9	271
74	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2305-2316	27.4	214
73	Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. *Brain*, **2015**, 138, 772-83	11.2	169
72	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. *Alzheimer's and Dementia*, **2015**, 11, 865-84	1.2	132
71	Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. *Alzheimer's and Dementia*, **2018**, 14, 1193-1203	1.2	111
70	Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. *Brain*, **2014**, 137, 1550-61	11.2	109
69	Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. *JAMA Neurology*, **2015**, 72, 446-54	17.2	103
68	Continuous femoral nerve blocks: varying local anesthetic delivery method (bolus versus basal) to minimize quadriceps motor block while maintaining sensory block. *Anesthesiology*, **2011**, 115, 774-81	4.3	103
67	Estimating long-term multivariate progression from short-term data. *Alzheimer's and Dementia*, **2014**, 10, S400-10	1.2	101
66	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β *Alzheimer's and Dementia*, **2017**, 13, 1004-1012	1.2	96
65	Parental ability to discriminate the weight status of children: results of a survey. *Pediatrics*, **2007**, 120, e112-9	7.4	89
64	Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 747-755	18.1	87
63	The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. *Alzheimer's and Dementia*, **2010**, 6, 257-64	1.2	85

62	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. *JAMA Neurology*, **2020**, 77, 735-745	17.2	81
61	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2014**, 1, 534-43	5.3	78
60	Continuous peripheral nerve blocks: is local anesthetic dose the only factor, or do concentration and volume influence infusion effects as well?. *Anesthesiology*, **2010**, 112, 347-54	4.3	76
59	Design and implementation of a randomized controlled social and mobile weight loss trial for young adults (project SMART). *Contemporary Clinical Trials*, **2014**, 37, 10-8	2.3	72
58	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. *Frontiers in Behavioral Neuroscience*, **2015**, 9, 239	3.5	60
57	Continuous femoral nerve blocks: decreasing local anesthetic concentration to minimize quadriceps femoris weakness. *Anesthesiology*, **2012**, 116, 665-72	4.3	60
56	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. *Alzheimer's and Dementia*, **2018**, 14, 1077-1087	1.2	52
55	Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. *Alzheimer's and Dementia*, **2015**, 11, 734-9	1.2	49
54	Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model. *Contemporary Clinical Trials*, **2015**, 42, 185-95	2.3	45
53	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 570-580	1.2	43
52	Emerging β-amyloid pathology and accelerated cortical atrophy. *JAMA Neurology*, **2014**, 71, 725-34	17.2	43
51	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. *Alzheimer's and Dementia*, **2015**, 11, 823-31	1.2	41
50	Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System. *Pain Practice*, **2017**, 17, 753-762	3	41
49	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 396-406	17.2	41
48	Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. *JAMA Neurology*, **2015**, 72, 554-60	17.2	39
47	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. *Neurology*, **2016**, 86, 1887-96	6.5	37
46	Pediatricians' weight assessment and obesity management practices. *BMC Pediatrics*, **2009**, 9, 19	2.6	35
45	Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. *Brain Communications*, **2020**, 2, fcaa007	4.5	32

44	The transitional association between β-amyloid pathology and regional brain atrophy. *Alzheimer's and Dementia*, **2015**, 11, 1171-9	1.2	29
43	Students at Risk for Being Reported for Cheating. *Journal of Academic Ethics*, **2015**, 13, 217-228	1.5	29
42	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 534-47	5.3	25
41	The relative efficiency of time-to-threshold and rate of change in longitudinal data. *Contemporary Clinical Trials*, **2011**, 32, 685-93	2.3	24
40	Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 45, 1175-84	4.3	23
39	Continuous femoral nerve blocks: the impact of catheter tip location relative to the femoral nerve (anterior versus posterior) on quadriceps weakness and cutaneous sensory block. *Anesthesia and Analgesia*, **2012**, 115, 721-7	3.9	23
38	Bayesian latent time joint mixed effect models for multicohort longitudinal data. *Statistical Methods in Medical Research*, **2019**, 28, 835-845	2.3	23
37	Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. *Neurobiology of Aging*, **2016**, 48, 172-181	5.6	22
36	Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. *JAMA Neurology*, **2021**, 78, 293-301	17.2	21
35	Predicting the course of Alzheimer's progression. *Brain Informatics*, **2019**, 6, 6	5.9	18
34	Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). *Journal of Alzheimer's Disease*, **2019**, 70, 131-138	4.3	16
33	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. *Alzheimer's and Dementia*, **2015**, 11, 1069-79	1.2	16
32	Applications of Neuroimaging to Disease-Modification Trials in Alzheimer's Disease. *Behavioural Neurology*, **2009**, 21, 129-136	3	16
31	A randomized, triple-masked, active-controlled investigation of the relative effects of dose, concentration, and infusion rate for continuous popliteal-sciatic nerve blocks in volunteers. *British Journal of Anaesthesia*, **2015**, 114, 121-9	5.4	15
30	Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 256-63	2.5	15
29	The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults. *Annals of Clinical and Translational Neurology*, **2020**, 7, 776-785	5.3	15
28	Continuous Transversus Abdominis Plane Nerve Blocks: Does Varying Local Anesthetic Delivery Method-Automatic Repeated Bolus Versus Continuous Basal Infusion-Influence the Extent of Sensation to Cold?: A Randomized, Triple-Masked, Crossover Study in Volunteers. *Anesthesia and Analgesia*, **2017**, 124, 1298-1303	3.9	14
27	F3-04-01: The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease **2012**, 8, P425-P426		14

26	The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. *journal of prevention of Alzheimer's disease, The*, **2021**, 8, 59-67	3.8	14
25	Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials. *Journal of Nutrition, Health and Aging*, **2012**, 16, 360-4	5.2	13
24	Developing dementia prevention trials: baseline report of the Home-Based Assessment study. *Alzheimer Disease and Associated Disorders*, **2013**, 27, 356-62	2.5	13
23	The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. *journal of prevention of Alzheimer's disease, The*, **2020**, 7, 208-212	3.8	11
22	Cross-validation of optimized composites for preclinical Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 123-129	6	9
21	Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. *journal of prevention of Alzheimer's disease, The*, **2020**, 7, 213-218	3.8	9
20	Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 657-668	5.2	9
19	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. *Neurodegenerative Diseases*, **2018**, 18, 173-190	2.3	8
18	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. *NeuroImage*, **2019**, 186, 446-454	7.9	8
17	The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 308-318	6	6
16	Time between milestone events in the Alzheimer's disease amyloid cascade. *NeuroImage*, **2021**, 227, 117676	7.9	5
15	Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. *Alzheimer's and Dementia*, **2018**, 14, 1397-1405	1.2	5
14	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. *Alzheimer's and Dementia*, **2019**, 15, 615-624	1.2	4
13	Requiring an amyloid-β-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. *Alzheimer's and Dementia*, **2011**, 7, 245-6; author reply 247-9	1.2	4
12	Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2021**, 7, e12135	6	4
11	Continuous Popliteal-Sciatic Blocks for Postoperative Analgesia: Traditional Proximal Catheter Insertion Superficial to the Paraneural Sheath Versus a New Distal Insertion Site Deep to the Paraneural Sheath. *Anesthesia and Analgesia*, **2019**, 128, e104-e108	3.9	3
10	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12118	5.2	3
9	Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial. *Regional Anesthesia and Pain Medicine*, **2021**, 46, 773-778	3.4	3

8	Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. *Alzheimer's and Dementia*, **2020**, 16, 797-803	1.2	1
7	Disease progression models for dominantly-inherited Alzheimer's disease. *Brain*, **2018**, 141, 1244-1246	11.2	1
6	Time between milestone events in the Alzheimer's disease amyloid cascade		1
5	Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume.. *GeroScience*, **2022**, 1	8.9	1
4	O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers **2013**, 9, P521-P522		0
3	Statistics and Clinical Data Analysis: A Reference Guide **2011**, 651-672		
2	Asynergistic Regression Based on Maximized Rank Correlation. *Communications in Statistics Part B: Simulation and Computation*, **2007**, 37, 92-105	0.6	
1	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.. *journal of prevention of Alzheimer's disease, The*, **2022**, 9, 255-261	3.8	